{
  "docId": "019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "docSlug": "58255c61d2bdadc3239a5fe01efc41e1",
  "documentTitle": "BioNTech | Results Presentation Deck | 43 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-08-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 26,
  "pageCount": 43,
  "prevPage": 25,
  "nextPage": 27,
  "slideType": "problem_statement",
  "function": "diagnose_problem",
  "density": "dense",
  "nDataPoints": 13,
  "notes": "The slide uses a geographic map to illustrate disease prevalence and a table to highlight low ORR and mOS for existing therapies.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-5aa5-74ef-a452-60fcbf49cdc6/26",
  "deckHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6",
  "deckJsonHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6.json",
  "deckAnchorHref": "/decks/019de071-5aa5-74ef-a452-60fcbf49cdc6#slide-26",
  "components": [
    {
      "bbox": {
        "h": 0.3,
        "w": 0.35,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "image",
      "text": "Global map of HPV-attributable cancer cases",
      "attrs": null,
      "subkind": "map",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "663b10d2-c76e-4bcf-a49c-8e7e769af4a6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.05,
        "y": 0.63
      },
      "kind": "list",
      "text": "Several types: HNSCC, Cervical, Anal, Vulvar, Vaginal, Penile. HNSCC is the sixth most common cancer worldwide. Oropharyngeal is most common HNSCC.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "923c7d71-680e-4026-a048-166e0de801b1",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.48,
        "y": 0.28
      },
      "kind": "list",
      "text": "HPV16+ HNSCC typically occur in younger people. >60% of patients diagnosed with late-stage HNSCC. Current treatment options carry significant treatment burden.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ee451ad6-e5bf-455e-aaf3-7dd4df5d5547",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.05,
        "y": 0.9
      },
      "kind": "source-note",
      "text": "References 1-6 provided at the bottom of the slide.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "b5909628-0e49-4745-a4d9-bceb03128d28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.2,
        "w": 0.45,
        "x": 0.48,
        "y": 0.62
      },
      "kind": "table",
      "text": "Current SOC for recurrent/metastatic HNSCC: pembrolizumab, nivolumab, chemotherapy with ORR, mOS, and mPFS metrics.",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1b59cffb-f413-4b73-8e13-c144b858b940",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.7,
        "x": 0.04,
        "y": 0.08
      },
      "kind": "title",
      "text": "BNT113: Unmet medical need for HPV-Associated HNSCC",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "67f48689-e9bd-4ea0-9598-16c25c0dbeeb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "c52ae720-b129-4528-a21f-c6e1977a1d3a",
      "evidence": "table/data: Current SOC for recurrent/metastatic HNSCC: pembrolizumab, nivolumab, chemotherapy with ORR, mOS, and mPFS metrics.",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [
    {
      "to": 42,
      "from": 7,
      "name": "Golden Circle",
      "slug": "11-golden-circle",
      "bestFor": "Visionary leadership, brand positioning, mission statements",
      "matchId": "6afc8369-9bbf-45e1-a77c-ba4d4e30b836",
      "evidence": "The document uses the Golden Circle framework to explain its vision, strategy, and achievements",
      "position": 0,
      "objective": "To explain why BioNTech's vision and strategy are important for the future of immunotherapy",
      "structure": "The Why (Belief) -> The How (Process) -> The What (Result)",
      "confidence": 0.7,
      "description": "Invert the typical pitch by starting with why you exist, rather than what you do"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}